Post-stroke pneumonia at the stroke unit – a registry based analysis of contributing and protective factors

Karl Matz1,2*, Leonhard Seyfang1, Alexandra Dachenhausen1, Yvonne Teuschl1, Jaakko Tuomilehto1,3,4, Michael Brainin1,2 and MD for the Austrian Stroke Unit Registry Collaborators

Abstract

Background: To investigate prevalence and risk factors for post stroke pneumonia (PSP) in patients with acute ischemic stroke treated at stroke units (SU).

Method: We analysed data from the Austrian Stroke Unit registry concerning admissions from January 2003 to December 2013 and assessed the prevalence of PSP at the stroke unit. Patients with and without PSP were compared in univariate and multivariate models searching for factors associated with the occurrence of PSP at the SU.

Results: Three thousand one hundred eleven patients (5.2%) of 59,558 analysed patients were diagnosed with PSP. While age and stroke severity were non-modifiable factors associated with PSP, modifiable risk factors included chronic alcohol consumption and atrial fibrillation. Patients who developed neurological, cardiac, and other infective complications showed a higher prevalence of PSP, an increased prevalence was also found in connection with the placement of nasogastric tubes or urinary catheters. Female sex, left hemispheric stroke, cryptogenic stroke pathogenesis and additionally, treatment with lipid lowering drugs were factors associated with a lower PSP prevalence.

Conclusion: Pneumonia in acute ischemic stroke is associated with a variety of modifiable and unmodifiable factors that allow to identify patients at high risk of developing PSP and to focus on early preventive measures at the SU. Further studies could use the results of this study to explore potential benefits of specific interventions targeted at these factors.

Keywords: Acute ischemic stroke, Stroke unit, Pneumonia, Respiratory infection, Risk factors

Background

Pneumonia is a frequently encountered problem affecting stroke patients. Whereas in stroke registries, a prevalence of post stroke pneumonia (PSP) from 2% [1] to 7.5% [2] has been found, among patients participating in randomized controlled trials PSP was encountered in 10 to 14% [3, 4]. In prospective cohorts of patients with acute stroke chest infection occurred with a prevalence between 7.4 and 12% [5]. A meta-analysis [6] covering 87 studies with 137817 patients found an overall prevalence of 10%. In a large Chinese cohort [7] pneumonia was the most common medical complication with a prevalence of 11.4%. A significantly higher prevalence of PSP has been found in cohorts of thrombolysed stroke patients [8] and patients treated at intensive care units (ICUs) [9, 10], reaching the highest rate with 28% among artificially ventilated patients [11].

In a metaanalysis [12] of studies from 2000 to 2015 the five most important risk factors for development of PSP were: multiple vertebrobasilar stroke, National Institutes of Health Stroke Scale score (NIHSS) >15 points, mechanical ventilation, nasogastric tube use and dysphagia. Other risk factors found in case control studies were age [13, 14], dysarthria [12], chronic lung disease [13] or pretreatment with proton pump inhibitors [15]. In
respect of anatomical characteristics lesion size [16], basal ganglia infarction [17] and hemorrhagic transformation of infarction were factors predisposing to PSP.

Aspiration due to dysphagia is thought to be a key component of the pathogenesis of PSP. A metaanalysis of seven studies with 891 patients has shown that dysphagia confers a more than threefold increased relative risk (RR) for PSP, dysphagia with aspiration in swallowing test a more than tenfold increased risk [18].

PSP is associated with reduced functional outcome [19], prolonged stay in hospital [20] and increased risk of death [21]. The pooled odds ratio for in-hospital mortality was 3.62 in a metaanalysis [6] of four studies and a recent study found PSP to be the medical complication most strongly associated with death or dependency after recurrent stroke [22].

**Purpose of the study**
The objective of the study was to analyse and compare patients with and without pneumonia during the stay at the SU in order to find relevant patients characteristics or stroke unit procedures predisposing to or being associated with PSP.

**Methods**
The study was designed as a case–control type analysis of data from the Austrian Stroke Unit Registry (ASUR) that prospectively collects data from patients with acute stroke admitted to SUs in Austria nationwide. The setup and method of this registry have been previously described [23].

In short, the ASUR is a prospective online registry of all acute stroke patients admitted to the SU network. It comprises records of stroke patients from meanwhile 38 Austrian SUs that have been collected continuously since 2003. The ASUR is financed by the Federal Ministry of Health and is centrally administered by the Gesundheit Österreich GmbH. Participating Austrian SUs document anonymized stroke-relevant data in the registry. All Scientific analyses are approved and supervised by a steering committee. Quality is regularly assessed by online analysis and national SU user and benchmarking meetings. For each SU admission data on stroke onset, severity, and subtype, known risk factors, imaging modalities, complications, treatments and outcome variables are recorded. Vascular risk factors were determined by reviewing medical history and prestroke medication, or assessed and newly diagnosed during the stay at the SU. The risk factors recorded were hypertension, hypercholesterolemia, diabetes mellitus, previous stroke, atrial fibrillation, myocardial infarction, other cardiac diseases, peripheral arterial disease, smoking and regular alcohol consumption. Hypertension was defined by a history of known hypertension with a systolic blood pressure ≥140 mmHg or diastolic blood pressure ≥90 mmHg (according to the criteria of the Seventh Report of Joint National Committee on Prevention and Detection, Evaluation, and Treatment of High Blood Pressure) [24], or a presence of antihypertensive drug treatment. Hypercholesterolemia was defined by a history of total cholesterol level ≥200 mg/dL or in the blood sample taken during hospital stay or a presence of lipid-lowering therapy. Lipid lowering treatment status was entered positive if either treatment was continued or newly prescribed. Diabetes mellitus was defined according to the World Health Organization [25] if the fasting plasma glucose level ≥126 mg/dL or 2 h plasma glucose level ≥200 mg/dL have been reported in the medical history or if patients were treated with insulin or oral hypoglycaemic agents. Smoking was defined as any habitual, not casual, consumption of cigarettes, pipes or cigars. Regular alcohol consumption (moderate or more) was defined as estimated average consumption >1 standard drink per day (>500 mL beer or >250 mL wine) according to national guidelines [26]. Atrial fibrillation, if not known before stroke, was diagnosed using ECG monitoring on the SU. Stroke types were classified based on neuroimaging (CT or MRI) findings according to the International Classification of Diseases (ICD)-10 code into ischemic stroke (I63) or primary intracerebral haemorrhage (I61). Stroke cause was classified into five subtypes (macroangiopathy, cardioembolism, microangiopathy, other determined etiology, and undetermined etiology) according to the Trial of Org 10172 in Acute Stroke Treatment (TOAST) criteria [27]. National Institute of Health Stroke Scale (NIHSS) was used to determine clinical severity of the stroke event on admission and at discharge from the SU. Functional status was measured by Barthel index and modified Rankin scale on admission, at discharge from the SU and at follow-up after three months. The follow-up was done by telephone interview of patients or caregivers in most cases.

Pneumonia was recorded as one of several clinical complications during the stay at the SU and was classified as such by the treating physician usually based on clinical symptoms of lung infection in combination with clinical sings such as rales on chest auscultation and chest X ray findings suggestive for pneumonia supported by elevation of inflammatory markers in laboratory tests. This follows in approximation the recently proposed adapted Centers for Disease Control and Prevention guidelines for the diagnosis of stroke associated pneumonia [28].

**Statistical methods**
Group differences were tested with the Chi-square test for independence in case of categorical variables and with the Wilcoxon rank sum test for equality of the location parameter for numeric variables. A multivariate
logistic regression model assessed the relationship between the dichotomous target variable PSP and various explanatory variables. Variable selection was done by the bidirectional stepwise variable selection procedure, optimizing the Bayesian information criterion (BIC). The start model was the trivial model, including just the intercept. All potential explanatory variables that were available for the variable selection are listed in Additional file 1: Table S1. The final model, resulting from the variable selection procedure, is also given in Additional file 1: Table S1. All data were processed using the statistical environment R, version 2.15.2 [29].

The second model was restricted to all cases whose status of lipid lowering therapy has been entered into the data registry since 2007 (n = 47321), thus 12237 patients were excluded. Explanatory variables of this model are listed in Additional file 1: Table S2. A description of the data selection process with frequencies of included variables, univariate comparisons and multivariate regression models is provided with Additional file 2.

**Results**

From 2003 until December 2013, data from 68583 patients with acute ischemic stroke were entered into the ASUR. Complete data sets for the SU period were available for 59558 (87 %) patients of whom 3111 (5.2 %) had PSP during the stay at the SU. The mean (or median) length of stay at the SU was 4.2 days for all patients. Clinical and demographic variables are listed in Table 1.

The univariate comparison between the group with and without PSP showed that patients with PSP were

| Table 1 Risk factors | Pneumonia at the SU | | | |
|---------------------|--|--|--|--|
| Patient characteristics | No (94.8 %) | Yes (5.2 %) | | |
| Age, y, median (interquartile range) | 72.9 (62.8, 81.3) | 79.8 (72, 85.1) | <0.001 | |
| Female sex, n (%) | 26521 (47) | 1457 (46.8) | 0.87 | 0.51–0.61 |
| Time onset-admission, median (interquartile range) | 120 (61, 280) | 90 (57, 156) | <0.001 | |
| Stroke syndrome, n (%) | | | | |
| LACS | 17592 (31.2) | 362 (11.6) | <0.001 | |
| PACS | 21627 (38.3) | 1214 (39.7) | 0.428 | |
| TACS | 5678 (10.1) | 1069 (34.4) | <0.001 | |
| POCS | 9555 (16.9) | 386 (12.4) | <0.001 | |
| mRS 0 before stroke, n (%) | 39601 (70.2) | 1507 (48.4) | <0.001 | |
| NIHSS on admission, median (interquartile range) | 3 (1, 7) | 14 (8, 20) | <0.001 | |
| Left hemisphere | 25692 (45.5) | 1446 (46.5) | 0.293 | 0.78–0.93 |
| Right hemisphere | 19853 (35.2) | 1250 (40.2) | <0.001 | |
| Both hemispheres | 987 (1.7) | 67 (2.2) | 0.095 | |
| Brainstem or cerebellum | 9915 (17.6) | 348 (11.1) | <0.001 | |
| Atrial Fibrillation, n (%) | 14031 (24.9) | 1596 (51.3) | <0.001 | 1.15–1.38 |
| Previous stroke, n (%) | 13171 (23.3) | 917 (29.5) | <0.001 | 1.26 |
| Hypertension, n (%) | 44776 (79.3) | 2608 (83.8) | <0.001 | |
| Diabetes, n (%) | 14041 (24.9) | 954 (30.7) | <0.001 | |
| Coronary heart disease, % | 5108 (9.0) | 426 (13.7) | <0.001 | |
| Peripheral arterial disease, n (%) | 3822 (6.8) | 311 (10.0) | <0.001 | |
| Regular alcohol use, n (%) | 4501 (8.0) | 290 (9.3) | 0.007 | 1.3–1.75 |
| Smoking, n (%) | 10346 (18.3) | 449 (14.4) | <0.001 | |
| Hypercholesterolemia, n (%) | 30754 (54.5) | 1440 (46.3) | <0.001 | |

LACS denotes lacunar syndrome, PACS partial anterior circulation syndrome, TACS total anterior circulation syndrome, POCS posterior circulation syndrome, NIHSS National Institute of Health Stoke Scale, mRS modified Rankin scale. Numbers are n and % or median and interquartile range, as indicated. OR denotes odds ratio, CI confidence interval. Multivariate analysis is continued in Table 2.
older (79.8 vs 72.9 %, \(p<0.001\)), less often functionally unimpaired before the stroke event (mRS 0 48.4 vs 72.9 %, \(p<0.001\)) and had more severe strokes (median NIHSS on admission 14 vs 3, \(p<0.001\)). Hypertension, diabetes mellitus, and history of stroke, coronary heart disease and atrial fibrillation were significantly more common among patients with PSP (51.3 vs. 24.9 %), whereas the prevalence of hypercholesterolemia and smoking was lower.

Patients with PSP had been more often treated with thrombolysis (22 vs. 13.9 %, \(p<0.001\)), continuous intravenous insulin treatment (4.2 vs 0.8 %, \(p<0.001\)), insulin injections or with intravenous antihypertensive agents (12.2 vs 3.8 %, \(p<0.001\)). Antiplatelets and lipid lowering agents had been less often administered to patients with PSP (50.2 vs 63.8 %, \(p<0.001\) resp. 73.3 vs 80.4 %, \(p<0.001\)). Invasive procedures like endotracheal intubation (4.6 vs 0.7 %, \(p<0.001\)), urinary catheter installation (79.4 vs 27.3 %, \(p<0.001\)), percutaneous gastrostomy (5.6 vs. 0.5 %, \(p<0.001\)) or particular insertion of nasogastric tubes (47 vs 6.8 %, \(p<0.001\)) were performed in much higher frequencies in the PSP patients (Table 2).

Patients with PSP were discharged from the SU significantly later (5 days, IQR 3–9 days vs. 3 days, interquartile range IQR 1–4, \(p<0.001\)), had a significantly higher median NIHSS (13 vs 2, \(p<0.001\)) and a lesser median decrease in NIHSS between admission and discharge from the SU than patients without PSP (0 vs 1, \(p<0.001\)). In the univariate comparison, every complication listed in the registry occurred more often in stroke patients with PSP (Table 2).

For the three-month follow up data from only 24136 (40.5 %) patients were available. Among these, patients with pneumonia at the SU had a more than fivefold higher mortality than patients without PSP (42.1 vs. 7.5 %, \(p<0.001\), OR 2.99, 95%CI 2.53–3.54, multivariate model, see table in Additional file 3).

### Table 2: Treatment and complications

| Treatment and complications                  | No              | Yes             | Univariate analysis | Multivariate analysis |
|----------------------------------------------|-----------------|-----------------|--------------------|----------------------|
| Treatment and complications                  | 56447 (94.8 %)  | 3111 (5.2 %)    | \(p<0.001\)        |                      |
| Pneumonia at the SU                          |                 |                 | \(p<0.001\)        |                      |
| iv-Thrombolytic therapy, n (%)               | 7822 (13.9)     | 685 (22)        | \(p<0.001\)        | 1.22–1.98            |
| Iv Insulin, n (%)                            | 464 (0.8)       | 131 (4.2)       | \(p<0.001\)        | 1.22–1.62            |
| Iv Antihypertensive drugs, n (%)             | 2163 (3.8)      | 379 (12.2)      | \(p<0.001\)        | 1.22–1.62            |
| Lipid lowering drugs, n (%)                  | 28657 (63.8)    | 1213 (50.2)     | \(p<0.001\)        |                      |
| Antiplatelet drugs, n (%)                    | 45408 (80.4)    | 2279 (73.3)     | \(p<0.001\)        |                      |
| Endotracheal intubation, n (%)               | 400 (0.7)       | 143 (4.6)       | \(p<0.001\)        |                      |
| Nasogastric tube, n (%)                      | 3864 (6.8)      | 1461 (47)       | \(p<0.001\)        | 2.84–3.47            |
| Percutaneous gastrostomy, n (%)              | 286 (0.5)       | 175 (5.6 %)     | \(p<0.001\)        | 2.02–3.14            |
| Urinary catheter, n (%)                      | 15382 (27.3)    | 2471 (79.4)     | \(p<0.001\)        | 2.15–2.72            |
| Physiotherapy, n (%)                         | 39207 (69.5)    | 2741 (88.1)     | \(p<0.001\)        |                      |
| NIHSS at discharge from SU, median, interquartile range | 2 (0, 5) | 13 (6, 20) | \(p<0.001\) |                      |
| Difference NIHSS admission – discharge, median, interquartile range | 1 (0, 3) | 0 (–1, 3) | \(p<0.001\) |                      |
| Speech therapy, n (%)                        | 29020 (51.4)    | 2337 (75.1)     | \(p<0.001\)        | 1.23–1.5             |
| Progressive stroke, n (%)                   | 1447 (2.6)      | 296 (9.5)       | \(p<0.001\)        | 1.47–2.01            |
| Recurrent stroke, n (%)                      | 425 (0.8)       | 82 (2.6)        | \(p<0.001\)        | 1.25–2.25            |
| SICH, n (%)                                  | 552 (1.0)       | 151 (4.9)       | \(p<0.001\)        |                      |
| Epileptic seizure, n (%)                     | 451 (0.8)       | 119 (3.8)       | \(p<0.001\)        | 1.36–2.23            |
| Brain edema, n (%)                           | 550 (1.0)       | 222 (7.1)       | \(p<0.001\)        | 1.29–1.9             |
| Septicemia, n (%)                            | 141 (0.2)       | 87 (2.8)        | \(p<0.001\)        | 2.47–4.83            |
| Urinary tract infection, n (%)               | 2042 (3.6)      | 444 (14.3)      | \(p<0.001\)        | 1.1–1.42             |
| Heart failure, n (%)                         | 661 (1.2)       | 328 (10.5)      | \(p<0.001\)        | 2.16–3.04            |
| Pulmonary embolism, n (%)                    | 85 (0.2)        | 42 (1.4)        | \(p<0.001\)        |                      |
| An Rhymma, n (%)                             | 1187 (2.1)      | 378 (12.2)      | \(p<0.001\)        | 1.79–2.43            |

NIHSS denotes National Institute of Health Stroke Scale, SICH symptomatic intracranial hemorrhage. Numbers are n and % or median and interquartile range, as indicated. OR denotes odds ratio, CI confidence interval. Multivariate analysis is continued from Table 1.
In the multiple regression model age and stroke severity were strongly associated with the occurrence of PSP. A potentially modifiable risk factor was history of atrial fibrillation and history of regular alcohol consumption (this difference between groups was very small and therefore not clinically important). Among treatment related factors treatment with intravenous insulin or antihypertensive agents, installation of urinary catheter, nasogastric tube insertion or percutaneous endoscopic gastrostomy (PEG) implantation were significantly associated with PSP. The highest OR was found for placement of nasogastric tubes (OR 3.14, %95 CI 2.84–3.41, \( p < 0.001 \)); 47 and 7 % of patients with and without PSP had nasogastric tubes. Most of the variables found to be associated with PSP in the univariate analysis were also associated with PSP in the multivariate analysis. In our model we found also factors associated with a with lower risk of PSP: i.e. female sex, left hemispheric stroke and cryptogenic stroke etiology.

In a second model restricted to the data of patients with known treatment status with lipid lowering drugs the same factors were associated with an increased risk of PSP as in the first model. Current treatment with lipid lowering drugs showed a lower risk for PSP (Fig. 1).

Discussion
We present the so far largest register-based study on the prevalence of PSP at SUs and a comparative analysis of patients with and without PSP.

Patients with PSP were older, had more often history of regular alcohol consumption and atrial fibrillation than those without PSP. Atrial fibrillation has already been found to be an independent risk factor for in-hospital acquired pneumonia [30], it is possible that this holds true also for stroke patients. Patients with PSP had also more severe strokes on admission, a higher NIHSS at time of discharge from the SU and a smaller improvement in NIHSS between admission and discharge from the SU. This can be interpreted that PSP not only occurs more often in severe strokes but also that early recovery is impaired in patients with PSP.

Several findings are interesting for further exploration: treatment with intravenous insulin is a possible surrogate marker for severe hyperglycemia in our cohort. The occurrence of infections is increased in hyperglycemia. Elevated blood glucose can lead to impairment of immune response on one hand, while on the other hand any infection can lead to a higher blood glucose levels, so the association of PSP with blood glucose may be reciprocal. Other authors consider an altered immune status [31] in stroke patients to be causal for the development of post stroke infections,
especially PSP. During the acute phase of ischemic stroke stress hormones, in particular cortisol and norepinephrine, are released and cause hyperglycemia and also lymphocyte dysfunction [32–34]. The ratio between the pro-inflammatory TNF- to the anti-inflammatory IL-10 is reduced during the period of the stroke related infection [35].

Similarly, treatment with antihypertensive agents may be a surrogate for acutely elevated blood pressure. However, in the ASUR no laboratory values are collected, hence no data on the actual blood glucose level and on the actual blood pressure were available.

The association with procedures such as urinary catheter installation and tube feeding are possibly related to severe illness leading to prolonged bed rest and dysphagia. One limitation of our study is that we could not document the temporal relationship between these procedures and the onset of PSP and it is possible that they are consequences of an elevated risk for PSP due to dysphagia rather than a risk factor for PSP. Recently a retrospective study of 536 patients and a large metaanalysis [12] also found placement of nasogastric tubes to be a strong predictor of respiratory infections in the first week after stroke [36].

Interestingly, some variables showed an inverse association with the risk of PSP. A healthier life style with lower alcohol consumption and smoking habits might contribute to the lower risk in women compared with men, although these factors were controlled for in the multivariate analysis. However, it is still possible that risk factors such as alcohol consumption or smoking are underreported in men. In a community based study in the elderly male sex was a risk factor for pneumonia [37], similarly among a cohort of trauma patients in another study [38]. In addition, female sex hormones can inhibit the inflammatory reaction against bacterial antigens and lead to less severe respiratory infections [39].

The lower risk for PSP in left sided stroke that we found might be an incidental finding, but one might speculate that patients with left-sided stroke usually do not show symptoms of unawareness or deficits such as unilateral hemineglect or anosognosia. These impairing symptoms can interfere with swallowing function and contribute to dysphagia and aspiration. One previous study [40] found a significant overrepresentation of right hemispheric strokes with insula involvement in patients with PSP, the authors argued that these lesions lead to an altered immune response.

Our study found an inverse association with lipid lowering treatment and PSP. A similar finding has been reported in a single center study of thrombolysed patients [41], but not by others [42]. A metaanalysis [43] of eight studies has shown a lower risk for pneumonia in people (not restricted to stroke patients) on treatment with statins compared with those not using statins, although there was substantial heterogeneity among the studies.

Limitations of the study are that parameters can only be included from the SU-based stroke registry and not from other sources of clinical data and that standardization of measurements and data collection methods is often limited. Furthermore, due to the case control design of the data comparison, the temporal relation between clinical events or variables is often difficult to determine. The ASUR is applying several methods to assure the data quality [44] to the extent it is possible in the routine clinical settings. Further limitations are the high number (59 %) of missing values concerning the three months follow up and that PSP was diagnosed without a clearly specified diagnostic algorithm by the treating physician on the basis of general clinical rules. In addition, later occurring cases of PSP after discharge from the SU were not recorded in the registry.

The strength of our study is the large and representative patient material with full national coverage and the low differences in treatment practices in the SUs that follow national and international guidelines and SOPs. Several preventive trials with antibiotics demonstrated reduction of infection rates in patients with acute stroke but failed to improve functional outcome [45–48]. Routine application of preventive antibiotic therapy is therefore not recommended. In this light, findings from studies like ours can help to identify factors that confer higher or lower risk for PSP in stroke patients treated at SUs and accordingly guide SU care.

Conclusion

We have shown that PSP is a frequent complication among stroke patients treated at the SU. We identified age, stroke severity, alcohol consumption and atrial fibrillation as predisposing risk factors. Components of stroke unit care and treatment procedures that are related to stroke severity, complications and dysphagia were also associated with PSP. Female sex, left hemispheric stroke, cryptogenic stroke pathogenesis and additionally, treatment with lipid lowering drugs had an inverse association with the risk of PSP. Factors both with higher and lower odds for PSP should be explored in further studies, using predetermined data collection with unbiased methodology and adequate control for confounding that are not always possible in register-based studies with limited data. Since this issue is important for stroke recovery and prognosis of patients, and for the costs associated with treatment of stroke patients, trials testing benefits of specific interventions targeted at these factors need to be designed.

Additional files

Additional file 1: Tables S1 and S2. (DOCX 381 KB)
Acknowledgements
Not applicable.

Funding
LS’s work is funded by the Austrian Stroke Society, none of the remaining authors received funding for this study.

Availability of data and materials
The dataset supporting the conclusions of this article is included within the article as additional word-file (additionalfile_originaldata.pdf). Raw data are under the ownership of the BiQG (Bundesinstitut für Qualität im Gesundheitswesen; National Institute for Quality in the Health Care System), any request for release of raw data of the ASUR has to be addressed to the BiQG.

Authors’ contributions
KM and MB conceived and designed the study. LS performed the statistical analysis. AD, YT and JT participated in its design and helped to draft the manuscript. KM wrote the manuscript. MB and YT revised the manuscript. All authors read and approved the final manuscript.

Authors’ information
Not applicable.

Competing interests
All authors declare to have no conflict of interest in conducting and publishing the study.

Consent for publication
Not applicable (no individual person’s data were used).

Ethics approval and consent to participate
In 2002, the Ministry of Health set up the Austrian Stroke Unit Registry (ASUR) together with the Austrian Stroke Society. Documentation of patients with TIA or stroke became mandatory for Stroke Units. In addition, it was recommended to have follow-up of patients after 3 months. All patient data are stored completely anonymized and analysed exclusively at the BiQG (Bundesinstitut für Qualität im Gesundheitswesen; National Institute for Quality in the Health Care System). Members of Austrian Stroke Units can apply to analyze certain aspects of the ASUR. An expert committee of the ASUR reviews and approves the proposal. All aspects of ethics and consent are completely regulated by national law as the registry is situated within an institution of the Austrian national health authorities. Therefore individual patients consent for data storage is not required as is approval by ethics committees. Our study protocol was reviewed and approved by the ASUR expert committee. All study procedures were performed with full permission by and in compliance with the ASUR and the BiQG.

Author details
1Department of Clinical Neurosciences and Preventive Medicine, Danube University Krems, Dr.-Karl-Dorrek-Str. 30, A-3500 Krems, Austria. 2Department of Neurology, University Clinic Tulln, Karl Landsteiner Privatuniversität für Gesundheitswissenschaften, Krems, Austria. 3Department of Chronic Disease Prevention, National Institute for Health and Welfare, 00271 Helsinki, Finland. 4Diabetes Research Group, King Abdullah University, 21589 Jeddah, Saudi Arabia.

References
1. Lakshminarayan K, Tsai AW, Tong X, Vazquez G, Peacock JM, George MG, et al. Utility of dysphagia screening results in predicting poststroke pneumonia. Stroke. 2010;41(12):2849–54.
2. Vermeij FH, Scholte op Reimer WJ, de Man F, van Oostenbrugge RJ, Franke CL, de Jong G, et al. Netherlands Stroke Survey Investigators. Stroke-associated infection is an independent risk factor for poor outcome after acute ischemic stroke: data from the Netherlands Stroke Survey. Cerebrovasc Dis. 2009;27(5):465–71.
3. Johnston KC, Li JY, Lyden PD, Hanson SK, Feasby TE, Adams RJ, et al. Medical and neurological complications of ischemic stroke: experience from the RANITAS trial. RANITAS Investigators. Stroke. 1998;29:447–53.
4. Arslanyan S, Weir CJ, Diener HC, Kaste M, Lees KR, for the GAIN International Steering Committee and Investigators. Pneumonia and urinary tract infection after acute ischaemic stroke: a tertiary analysis of the GAIN International trial. Eur J Neurol. 2004;11:49–53.
5. Kumar S, Selim MH, Caplan LR. Medical complications after stroke. Lancet Neurol. 2010;9:105–18.
6. Westendorp WP, Nederkoorn PJ, Vermeij JD, Dijkgraaf MG, van de Beek D. Post-stroke infection: a systematic review and meta-analysis. BMC Neurol. 2011;11:10. doi:10.1186/1471-2371-11-10.
7. Ji R, Wang D, Shen H, Pan Y, Liu G, Wang P, Wang Y, Li H, Wang Y, China National Stroke Registry (CNSR) Investigators. Interrelationship among common medical complications after acute stroke: pneumonia plays an important role. Stroke. 2013;44(12):3436–3444.
8. Bruening T, AHhaled M. Stroke-Associated Pneumonia in Thrombolysed Patients: Incidence and Outcome. J Stroke Cerebrovasc Dis. 2015;24(5):1052–3057. 15(001081).
9. Hilker R, Poetter C, Findeisen N, Sobesky J, Jacobs A, Neveling M, et al. Nosocomial pneumonia after acute stroke: implications for neurological intensive care medicine. Stroke. 2003;34:975–81.
10. Upadhya A, Thorevik N, Sena KN, Manthous C, Arnaoteng-Adjepong Y. Predictors and consequences of pneumonia in critically ill patients with stroke. J Crit Care. 2004;19:16–22.
11. Kasuya Y, Hargett JL, Lenhardt R, Heine MF, Rummell KS, et al. Ventilator-associated pneumonia in critically ill stroke patients: Frequency, risk factors, and outcomes. J Crit Care. 2010;26:273–9.
12. Yuan MZ, Li F, Tian X, Wang W, Jia M, Wang XF, et al. Risk factors for lung infection in stroke patients: a meta-analysis of observational studies. Expert Rev Anti Infect Ther. 2015;13:1289–98.
13. Sellars C, Bowie L, Bagg J, Sweeney MP, Miller H, Tilston J, et al. Risk factors for chest infection in acute stroke: a prospective cohort study. Stroke. 2007;38:281–91.
14. Finlayson CP, Kapral M, Hall R, Asllani E, Selchen D, Saposnik G, Canadian Stroke Network; Stroke Outcome Research Canada (SORCan) Working Group. Risk factors, inpatient care, and outcomes of pneumonia after ischemic stroke. Neurology. 2011;77:1388–45.
15. Marciuch C, Konutz AW, Lin E, Roth E, Welty L, Lovell L. Examination of selected clinical factors and medication use as risk factors for pneumonia during stroke rehabilitation: a case-control study. Am J Phys Med Rehabil. 2009;88:30–8.
16. Minnerup J, Wersching H, Brokinkel B, Dziewas R, Franke CL, de Jong G, et al. Netherlands Stroke Survey Investigators. Stroke ischaemic stroke: interrelationship among medical complications after post-stroke infection frequency. J Neurol Neurosurg Psychiatry. 2010;81:198–202.
17. Walter U, Knoblich R, Steinhagen H, Donat M, Benecke R, Kloth A. Predictors of pneumonia in acute stroke patients admitted to a neurological intensive care unit. J Neurol. 2007;254:1323–9.
18. Martino R, Foley N, Bhogal S, Diamant N, Speechley M, Teasell R. Dysphagia after stroke: incidence, diagnosis, and pulmonary complications. Stroke. 2005;36:2756–276.
19. Rohweder G, Elleker H, Salvesen O, Naalsund E, Indredavik B. Functional outcome after common poststroke complications occurring in the first 90 days. Stroke. 2014;45:6657–6667 (Epub ahead of print).
20. Ingeman A, Andersen G, Hundborg HH, Svendsen ML, Johnsen SP. In-hospital medical complications, length of stay, and mortality among stroke unit patients. Stroke. 2011;42:3214–8.
21. Kwan J, Hand P. Infection after acute stroke is associated with poor short-term outcome. Acta Neurol Scand. 2007;115:331–8.

Received: 1 September 2015 Accepted: 17 June 2016
Published online: 18 July 2016
22. Rohweder G, Elfeky H, Salvesen Ø, Naalsund E, Indredavik B. Functional outcome after common poststroke complications occurring in the first 90 days. Stroke. 2015;46(1):65–70.

23. Ferrari J, Knobfach M, Kiechl S, Williet J, Schnabl S, Seyfang L, et al. Austrian Stroke Unit Registry Collaborators. Early clinical worsening in patients with TIA or minor stroke: the Austrian Stroke Unit Registry. Neurology. 2010;74: 136–41.

24. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo Jr JL, et al. National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003;289:2560–72.

25. WHO Consultation. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus. Geneva: World Health Organization; 1999. Report No. 99.8.

26. Uhl A, Springer A. Studie über den Konsum von Alkohol und psychoaktiven Stoffen in Österreich unter Berücksichtigung problematischer Gebrauchsmuster - Repräsentativbehebung 1993/94 Datenband. Vienna: Bericht des LBI Sucht; 1996.

27. Adams Jr HP, Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL, et al. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke. 1993;24:35–41.

28. Smith CJ, Kishore AK, Vail A, Chamorro A, Garau J, Hopkins SJ, et al. Diagnosis of Stroke-Associated Pneumonia: Recommendations From the Pneumonia in Stroke Consensus Group. Stroke. 2015;25:STROKEAHA.115.009617.

29. R Development Core Team. R. A language and environment for statistical computing. Vienna: R Foundation for Statistical Computing; 2012. Available at: www.R-project.org.

30. Zhu J, Zhang X, Shi G, Yi K, Tan X. Atrial Fibrillation Is an Independent Risk Factor for Hospital-Acquired Pneumonia. PLoS One. 2013;8, e71141. doi:10.1371/journal.pone.0131782.

31. Urra X, Obach V, Chamorro A. Stroke induced immunodepression syndrome: from bench to bedside. Curr Mol Med. 2009;9:195–202.

32. Chamorro A, Arnau S, Vargas M, Obach V, Cervera A, Gómez-Choco M, et al. Catecholamines, infection, and death in acute ischemic stroke. J Neurol Sci. 2007;252:29–35.

33. Klehmet J, Harms H, Richter M, Prass K, Volk HD, Dimagli U, et al. Stroke-induced immunodepression and post-stroke infections: lessons from the preventive antibacterial therapy in stroke trial. Neuroscience. 2009;158:1184–93.

34. Vogelgesang A, Grunwald U, Langner S, Jack R, Bröker BM, Kessler C, et al. Analysis of lymphocyte subsets in patients with stroke and their influence on infection after stroke. Stroke. 2011;41:237–241.

35. Urra X, Obach V, Chamorro A. Stroke induced immunodepression syndrome: a manifestation of brain-induced immunodepression. Stroke. 2007;38:1097–103.

36. Biogen E, Langdon C, Brookes K, Blacker D. Dysphagia and factors associated with respiratory infections in the first week post stroke. Neuroepidemiology. 2014;43:140–4.

37. Juthani Mehta M, De Rekeneire N, Allroe H, Chen S, O’Leary JR, Health ABC Study, et al. Modifiable risk factors for pneumonia requiring hospitalization of community-dwelling older adults: the Health, Aging, and Body Composition Study. J Am Geriatr Soc. 2013;61:1111–8.

38. Gannon CJ, Pasquale M, Tracy JK, McCarter RJ, Napolitano LM. Male gender is associated with increased risk for postinjury pneumonia. Shock. 2004;21:410–4.

39. Falagas ME, Mourtzoukou EG, Vardakas KZ. Sex differences in the incidence and severity of respiratory tract infections. Respir Med. 2007;101:1845–63.

40. Kemmling A, Lev MH, Payavash S, Betensky RA, Qian J, Masrur S, et al. Hospital acquired pneumonia is linked to right hemispheric peri-insular stroke. PLoS One. 2013;8, e71141.

41. Schetz JF, Endres M, Heuschmann PU, Audebert HJ, Nothe CH. Reduced risk of poststroke pneumonia in thrombolysed stroke patients with continued statin treatment. Int J Stroke. 2012. doi:10.1111/j.1747-4949.2012.00864.

42. de Antonio LA R, Martínez-Sánchez P, Martínez-Martínez MM, Cazorla-García R, Sanz-Gallego I, Fuentes B, et al. Previous statins treatment and risk of post-stroke infections. Neurology. 2011;76(2):150–6.

43. Kwok CS, Yeong JK, Turner RM, Cavallazzi R, Singh S, Loke YK. Statins and associated risk of pneumonia: a systematic review and meta-analysis of observational studies. Eur J Clin Pharmacol. 2012;68:47–55.

44. Gassman JJ, Owen WW, Kuntz TE, Martin JP, Amoroso WP. Data quality assurance, monitoring, and reporting. Control Clin Trials. 1995;16(2 Suppl):104S–36S.

45. Westendorf WF, Vermeij JD, Zock E, Hooijenga J, Kruit ND, Bosboom HJ, et al. PASS investigators. The Preventive Antibiotics in Stroke Study (PASS): a pragmatic randomised open-label masked endpoint clinical trial. Lancet. 2015;18:1519–26.

46. Westendorf WF, Vermeij JD, Vermeij F, Den Hertog HM, Dippel DW, de Beek V, et al. Antibiotic therapy for preventing infections in patients with acute stroke. Cochrane Database Syst Rev. 2012;1:CD008330.

47. Harms H, Prass K, Meisel C, Klehmet J, Rogge W, Drenckhahn C, et al. Preventive antibacterial therapy in acute ischemic stroke: a randomized controlled trial. PLoS One. 2008;14(3). 10.1371/.

48. Lamp L, Boaz M, Gilad R, Lorberboym M, Dubbey R, Rapoport A, et al. Minocycline treatment in acute stroke: an open-label, evaluator-blinded study. Neurology. 2007;69:1404–10.

Submit your next manuscript to BioMed Central and we will help you at every step:
• We accept pre-submission inquiries
• Our selector tool helps you to find the most relevant journal
• We provide round the clock customer support
• Convenient online submission
• Maximum visibility for your research

Submit your manuscript at www.biomedcentral.com/submit